Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Podcasts

Listen to Scrip podcasts for our perspectives on biopharma R&D, deal-making, product strategies and other key commercial topics.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.

Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?

Scrip overviews biopharma deal-making in 2022 and discusses the Pfizer/Seagen merger and its ramifications for the remainder of 2023, with EF Hutton analyst Mike King and Mintz attorney Matt Gardella.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.

Chinese Language Podcast: 重磅交易, 亚太药企如何度过资本寒冬, 减肥药风口

The latest China biopharma trends, including recent multimillion dollar deals by biotech firms, companies preparing for the worst as the 'capital winter' lingers, and GLP-1 agents for obesity are discussed by Brian Yang in Beijing and Dexter Yan in Shanghai in this latest Chinese-language podcast.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: J&J’s Duarto on the importance of diversity; Teva’s views on its new risperidone launch; Almirall’s hopes for lebrikizumab; Biogen’s Viehbacher questions the need for spending on weight loss drugs; and Citeline’s annual R&D review looks at the current state of the global biopharma pipeline.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: strong growth in blockbuster ranks in 2022; Lilly’s donanemab slow cognitive decline; FDA approves first RSV vaccine; Pfizer anticipates revenue bolus from vaccines; and Astellas buys into ophthalmology.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: BMS names new CEO; Novartis culls pipeline; AstraZeneca taps Chinese innovation; Q2 approvals to look out for; and a look at deal-making trends in 2022.

Creating Best In Class Antivirals In Post-COVID China: Interview with Huahui Health CSO Li Wenhui

COVID-19 has highlighted the need for potent, safe and effective antiviral therapies for infectious diseases and now one well-known Chinese researcher is tackling hepatitis B and D though a homegrown drug discovery approach. He talks to Scrip in this wide-ranging audio interview.  

See All

ABOUT

Pharma Intelligence podcasts discuss key ideas and insights affecting biopharma and medtech, brought to you by our global team of editors. Listen on-demand to our perspectives on the latest industry developments.

FIND ALL PHARMA INTELLIGENCE PODCASTS ON:

MORE PODCASTS

UsernamePublicRestriction

Register